Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Knight Therapeutics raises Cdn$230mm in bought deal financing

Executive Summary

Specialty pharma company Knight Therapeutics Inc. raised Cdn$230mm ($179mm) in a bought deal financing of 28.75mm common shares (including full exercise of the over-allotment option of 3.75mm shares) at Cdn$8 ($6.24). The deal was done by an underwriting syndicate led by GMP Securities L.P.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO
    • Venture Financing

Related Companies